Lung Cancer Drug Setback

Unfortunately, Pfizer announced that its drug for late stage lung cancer treatment, Dacomitnib, failed in two late-stage studies.  Another stage is set to be reported in 2015.  See the report on this development at http://finance.yahoo.com/news/pfizer-cancer-drug-fails-2-133921000.html.

Speak Your Mind

*